Oruka Therapeutics (ORKA) Change in Accured Expenses (2010 - 2026)

Oruka Therapeutics' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$1.3 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 156.28% year-over-year to -$1.3 million in Q1 2026; TTM through Mar 2026 was $3.6 million, a 32.83% decrease from a year earlier, with the FY2025 full-year figure at $7.2 million, up 120.08% from the prior year.
• Change in Accured Expenses fell to -$1.3 million in Q1 2026 per ORKA's latest filing, from $2.2 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.8 million in Q3 2025 and bottomed at -$2.1 million in Q2 2025.
• The 5-year median for Change in Accured Expenses is $51000.0 (2022), against an average of $457235.3.
• Across the five-year window, Change in Accured Expenses tumbled 1388.89% in 2023 and soared 1142.22% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at -$342000.0 in 2022, then slipped by 24.85% to -$427000.0 in 2023, then soared by 484.54% to $1.6 million in 2024, then surged by 34.41% to $2.2 million in 2025, then sank by 159.08% to -$1.3 million in 2026.
• Per Business Quant, the three latest ORKA Change in Accured Expenses figures stand at -$1.3 million (Q1 2026), $2.2 million (Q4 2025), and $4.8 million (Q3 2025).